Insights

New Product Launch ANAVEON AG recently launched ANV419 in the OMNIA-2 study, showing their commitment to innovation and expanding their product portfolio in immuno-oncology. This presents an opportunity for collaborative partnerships and potential sales with healthcare providers and institutions looking for advanced cancer treatments.

Strategic Hiring With the appointment of Dr. Eduard Gasal as Chief Medical Officer, ANAVEON AG demonstrates a focus on strengthening their leadership team with clinical expertise. Leveraging this key personnel addition can open doors for business development professionals to engage in discussions with key opinion leaders and medical institutions seeking cutting-edge therapies for cancer.

Therapeutic Development ANAVEON AG's dedication to developing therapies for less immunogenic tumors, along with the success of ANV419, showcases their commitment to addressing unmet medical needs in oncology. This presents an opportunity for sales development representatives to engage with oncologists and healthcare providers seeking innovative solutions for challenging patient cases.

Market Expansion The market trend of expanding therapeutic potential by delivering IL-2 agonists to tumor fighting cells aligns with ANAVEON AG's strategy. Sales professionals can leverage this trend to position ANAVEON's offerings as part of the growing landscape of personalized and targeted therapies, appealing to healthcare providers looking for precision medicine solutions in oncology.

Funding Strength With a funding of $120 million and revenue in the range of $0-10 million, ANAVEON AG exhibits financial stability and growth potential. Business development professionals can utilize this information to build confidence in potential partners, investors, and customers, highlighting the company's ability to deliver long-term value and sustain impactful research and development efforts.

ANAVEON AG Tech Stack

ANAVEON AG uses 8 technology products and services including Google Font API, TweenMax, Open Graph, and more. Explore ANAVEON AG's tech stack below.

  • Google Font API
    Font Scripts
  • TweenMax
    Javascript Frameworks
  • Open Graph
    Miscellaneous
  • Yoast SEO
    Search Engines
  • X-XSS-Protection
    Security
  • HSTS
    Security
  • Bootstrap
    UI Frameworks
  • Apache
    Web Servers

Media & News

ANAVEON AG's Email Address Formats

ANAVEON AG uses at least 1 format(s):
ANAVEON AG Email FormatsExamplePercentage
First.Last@anaveon.comJohn.Doe@anaveon.com
49%
First.MiddleLast@anaveon.comJohn.MichaelDoe@anaveon.com
1%
First.Middle@anaveon.comJohn.Michael@anaveon.com
1%
First.Last@anaveon.comJohn.Doe@anaveon.com
49%

Frequently Asked Questions

Where is ANAVEON AG's headquarters located?

Minus sign iconPlus sign icon
ANAVEON AG's main headquarters is located at Technologiepark Basel, Hochbergerstrasse 60C Basel, 4057 CH. The company has employees across 2 continents, including EuropeNorth America.

What is ANAVEON AG's official website and social media links?

Minus sign iconPlus sign icon
ANAVEON AG's official website is anaveon.com and has social profiles on LinkedIn.

How much revenue does ANAVEON AG generate?

Minus sign iconPlus sign icon
As of June 2024, ANAVEON AG's annual revenue reached $1.8M.

What is ANAVEON AG's SIC code NAICS code?

Minus sign iconPlus sign icon
ANAVEON AG's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ANAVEON AG have currently?

Minus sign iconPlus sign icon
As of June 2024, ANAVEON AG has approximately 25 employees across 2 continents, including EuropeNorth America. Key team members include Chief Executive Officer: A. K.Chief Business Officer: G. M. P.Chief Scientific Officer: C. H.. Explore ANAVEON AG's employee directory with LeadIQ.

What industry does ANAVEON AG belong to?

Minus sign iconPlus sign icon
ANAVEON AG operates in the Biotechnology Research industry.

What technology does ANAVEON AG use?

Minus sign iconPlus sign icon
ANAVEON AG's tech stack includes Google Font APITweenMaxOpen GraphYoast SEOX-XSS-ProtectionHSTSBootstrapApache.

What is ANAVEON AG's email format?

Minus sign iconPlus sign icon
ANAVEON AG's email format typically follows the pattern of . Find more ANAVEON AG email formats with LeadIQ.

How much funding has ANAVEON AG raised to date?

Minus sign iconPlus sign icon
As of June 2024, ANAVEON AG has raised $120M in funding. The last funding round occurred on Dec 16, 2021 for $120M.

When was ANAVEON AG founded?

Minus sign iconPlus sign icon
ANAVEON AG was founded in 2017.
ANAVEON AG

ANAVEON AG

Biotechnology ResearchBasel, Switzerland11-50 Employees

A start up based in Switzerland that develops biologics to modulate the functions of cytokines and provide substantial therapeutic benefits to cancer patients.

Section iconCompany Overview

Headquarters
Technologiepark Basel, Hochbergerstrasse 60C Basel, 4057 CH
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $120M

    ANAVEON AG has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Dec 16, 2021 in the amount of $120M.

  • $10M

    ANAVEON AG's revenue is in the range of $10M

Section iconFunding & Financials

  • $120M

    ANAVEON AG has raised a total of $120M of funding over 2 rounds. Their latest funding round was raised on Dec 16, 2021 in the amount of $120M.

  • $10M

    ANAVEON AG's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.